Search in:

Advanced search

mAbs Volume 5, 2013 - Issue 3

Submit an article Journal homepage

Open access

1,482

Views

CrossRef citations to date

Altmetric

Meeting Report

8^th Annual European Antibody Congress 2012

November 27–28, 2012, Geneva, Switzerland

Alain Beck Centre d’Immunologie Pierre Fabre; Saint-Julien en Genevois, FranceCorrespondence[email protected]

Paul J. Carter Genentech Inc.; South San Francisco, CA USA

Hans-Peter Gerber Pfizer Inc.; New York, NY USA

Alexey A. Lugovskoy Merimack; Pharmaceuticals, MA USA

Thierry Wurch Institut de Recherches SERVIER; Croissy-sur-Seine, France

Jagath R. Junutula Genentech Inc.; South San Francisco, CA USA

Roland E Kontermann Institute of Cell Biology and Immunology; University of Stuttgart; Stuttgart, Germany

Robert Mabry Adimab LLC; Lebanon, NH USA

show all

Pages 339-357 | Received 25 Feb 2013, Accepted 25 Feb 2013, Published online: 14 Mar 2013

Cite this article
https://doi.org/10.4161/mabs.24105

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415 - 6; http://dx.doi.org/10.4161/mabs.3.5.17334; PMID: 21785279
PubMed Web of Science ®Google Scholar
Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419 - 25; http://dx.doi.org/10.4161/mabs.20996; PMID: 22699226
PubMed Web of Science ®Google Scholar
Reichert JM. Which are the antibodies to watch in 2012?. MAbs 2012; 4:1 - 3; http://dx.doi.org/10.4161/mabs.4.1.18719; PMID: 22327425
PubMed Web of Science ®Google Scholar
Chan AC, Carter PJ. Antibody therapeutics for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301 - 16; http://dx.doi.org/10.1038/nri2761; PMID: 20414204
PubMed Web of Science ®Google Scholar
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al, CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109 - 19; http://dx.doi.org/10.1056/NEJMoa1113216; PMID: 22149875
PubMed Web of Science ®Google Scholar
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al, EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783 - 91; http://dx.doi.org/10.1056/NEJMoa1209124; PMID: 23020162
PubMed Web of Science ®Google Scholar
Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:185 - 97; http://dx.doi.org/10.4161/mabs.4.2.19000; PMID: 22453100
PubMed Web of Science ®Google Scholar
Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537 - 40; http://dx.doi.org/10.1038/305537a0; PMID: 6137772
PubMed Web of Science ®Google Scholar
Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26 - 35; http://dx.doi.org/10.1006/jmbi.1997.1116; PMID: 9231898
PubMed Web of Science ®Google Scholar
Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617 - 21; http://dx.doi.org/10.1093/protein/9.7.617; PMID: 8844834
PubMedGoogle Scholar
Merchant AM, Zhu ZP, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677 - 81; http://dx.doi.org/10.1038/nbt0798-677; PMID: 9661204
PubMed Web of Science ®Google Scholar
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715 - 25; http://dx.doi.org/10.1038/nri2155; PMID: 17703228
PubMed Web of Science ®Google Scholar
Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3 - 10; http://dx.doi.org/10.1016/j.ymeth.2005.01.001; PMID: 15848070
PubMed Web of Science ®Google Scholar
Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226 - 34; http://dx.doi.org/10.1038/nrd2804; PMID: 19247305
PubMed Web of Science ®Google Scholar
Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100:1566 - 72; http://dx.doi.org/10.1111/j.1349-7006.2009.01222.x; PMID: 19538497
PubMed Web of Science ®Google Scholar
Reusch D, Haberger M, Selman MH, Bulau P, Deelder AM, Wuhrer M, et al. High-throughput work flow for IgG Fc-glycosylation analysis of biotechnological samples. Anal Biochem 2013; 432:82 - 9; http://dx.doi.org/10.1016/j.ab.2012.09.032; PMID: 23026777
PubMed Web of Science ®Google Scholar
Diepold K, Bomans K, Wiedmann M, Zimmermann B, Petzold A, Schlothauer T, et al. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS One 2012; 7:e30295; http://dx.doi.org/10.1371/journal.pone.0030295; PMID: 22272329
PubMed Web of Science ®Google Scholar
Hensel M, Steurer R, Fichtl J, Elger C, Wedekind F, Petzold A, et al. Identification of potential sites for tryptophan oxidation in recombinant antibodies using tert-butylhydroperoxide and quantitative LC-MS. PLoS One 2011; 6:e17708; http://dx.doi.org/10.1371/journal.pone.0017708; PMID: 21390239
PubMed Web of Science ®Google Scholar
Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466 - 73; http://dx.doi.org/10.1074/jbc.M210665200; PMID: 12427744
PubMed Web of Science ®Google Scholar
Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog 2012; 28:608 - 22; http://dx.doi.org/10.1002/btpr.1548; PMID: 22473974
PubMed Web of Science ®Google Scholar
Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J 2008; 10:268 - 76; http://dx.doi.org/10.1208/s12248-008-9026-7; PMID: 18465252
PubMed Web of Science ®Google Scholar
Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M, et al. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 2011; 413:261 - 78; http://dx.doi.org/10.1016/j.jmb.2011.08.012; PMID: 21856311
PubMed Web of Science ®Google Scholar
Szebeni J, Alving CR. Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1999; 27:23 - 41; http://dx.doi.org/10.3109/10731199909117481; PMID: 10063436
PubMed Web of Science ®Google Scholar
Szebeni J. Hemocompatibility testing for nanomedicines. Eur J Nanomed 2012; 4:33 - 53
Google Scholar

References

Sapra P, Hooper AT, O’Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011; 20:1131 - 49; http://dx.doi.org/10.1517/13543784.2011.582866; PMID: 21599617
PubMed Web of Science ®Google Scholar
Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 2010; 28:2085 - 93; http://dx.doi.org/10.1200/JCO.2009.25.1900; PMID: 20308665
PubMed Web of Science ®Google Scholar
Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 2013; 12:38 - 47; http://dx.doi.org/10.1158/1535-7163.MCT-12-0603; PMID: 23223830
PubMed Web of Science ®Google Scholar
Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698 - 704; http://dx.doi.org/10.1200/JCO.2009.26.2071; PMID: 20421541
PubMed Web of Science ®Google Scholar
Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398 - 405; http://dx.doi.org/10.1200/JCO.2010.29.5865; PMID: 21172893
PubMed Web of Science ®Google Scholar
Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012; 118:5733 - 40; http://dx.doi.org/10.1002/cncr.27622; PMID: 22648179
PubMed Web of Science ®Google Scholar
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190 - 6; http://dx.doi.org/10.1200/JCO.2011.38.0402; PMID: 22614995
PubMed Web of Science ®Google Scholar

References

Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653 - 63; http://dx.doi.org/10.4161/mabs.21379; PMID: 22925968
PubMed Web of Science ®Google Scholar

References

Glassy MC, Hagiwara H. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Hum Antibodies 2009; 18:127 - 37; PMID: 19996527
PubMedGoogle Scholar
Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010; 5:e9106; http://dx.doi.org/10.1371/journal.pone.0009106; PMID: 20161706
PubMed Web of Science ®Google Scholar
Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246 - 51; http://dx.doi.org/10.1126/science.1171491; PMID: 19251591
PubMed Web of Science ®Google Scholar
Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843 - 50; http://dx.doi.org/10.1126/science.1204839; PMID: 21737702
PubMed Web of Science ®Google Scholar
Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337:1343 - 8; http://dx.doi.org/10.1126/science.1222908; PMID: 22878502
PubMed Web of Science ®Google Scholar
Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113:316 - 28; http://dx.doi.org/10.1002/ijc.20543; PMID: 15386423
PubMed Web of Science ®Google Scholar
Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007; 43:1318 - 27; http://dx.doi.org/10.1016/j.ejca.2007.03.009; PMID: 17451939
PubMed Web of Science ®Google Scholar
Corvaia N, Beck A, Caussanel V, Goetsch L. Insulin-like growth factor receptor type I as a target for cancer therapy. Front Biosci (Schol Ed) 2013; 5:439-50.:439-450.
Google Scholar
Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012; 104:975 - 81; http://dx.doi.org/10.1093/jnci/djs258; PMID: 22761272
PubMed Web of Science ®Google Scholar
Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012; 11:17 - 8; http://dx.doi.org/10.1038/nrd3630; PMID: 22212671
PubMed Web of Science ®Google Scholar
Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 2002; 16:240 - 2; PMID: 11772942
PubMed Web of Science ®Google Scholar
Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med 2009; 15:1088 - 92; http://dx.doi.org/10.1038/nm.1966; PMID: 19684583
PubMed Web of Science ®Google Scholar
Bowes T, Hanley SA, Liew A, Eglon M, Mashayekhi K, O’Kennedy R, et al. Developing cell-specific antibodies to endothelial progenitor cells using avian immune phage display technology. J Biomol Screen 2011; 16:744 - 54; http://dx.doi.org/10.1177/1087057111407067; PMID: 21593485
PubMed Web of Science ®Google Scholar
Finlay WJ, Bloom L, Cunningham O. Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens. Methods Mol Biol 2011; 681:383 - 401; http://dx.doi.org/10.1007/978-1-60761-913-0_21; PMID: 20978977
PubMedGoogle Scholar
Shih HH, Tu C, Cao W, Klein A, Ramsey R, Fennell BJ, et al. An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition. J Biol Chem 2012; 287:44425 - 34; http://dx.doi.org/10.1074/jbc.M112.415935; PMID: 23148212
PubMed Web of Science ®Google Scholar
Benson DM Jr., Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011; 118:6387 - 91; http://dx.doi.org/10.1182/blood-2011-06-360255; PMID: 22031859
PubMed Web of Science ®Google Scholar
Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120:4317 - 23; http://dx.doi.org/10.1182/blood-2012-06-437558; PMID: 23002117
PubMed Web of Science ®Google Scholar
Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120:4324 - 33; http://dx.doi.org/10.1182/blood-2012-06-438028; PMID: 23033266
PubMed Web of Science ®Google Scholar
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 2012; 18:3834 - 45; http://dx.doi.org/10.1158/1078-0432.CCR-12-0715; PMID: 22615450
PubMed Web of Science ®Google Scholar
Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007; 67:8882 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-07-0696; PMID: 17875730
PubMed Web of Science ®Google Scholar
Wurch T, Pierré A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol 2012; 30:575 - 82; http://dx.doi.org/10.1016/j.tibtech.2012.07.006; PMID: 22944617
PubMed Web of Science ®Google Scholar
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436 - 49; http://dx.doi.org/10.1016/j.jmb.2010.04.001; PMID: 20382161
PubMed Web of Science ®Google Scholar
Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117:4542 - 51; http://dx.doi.org/10.1182/blood-2010-09-306449; PMID: 21300981
PubMed Web of Science ®Google Scholar
Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926 - 34; http://dx.doi.org/10.1182/blood-2009-10-248609; PMID: 20439625
PubMed Web of Science ®Google Scholar
Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160 - 70; http://dx.doi.org/10.1016/j.ccr.2010.06.014; PMID: 20708157
PubMed Web of Science ®Google Scholar

References

Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 58:1195 - 201; PMID: 9515805
PubMed Web of Science ®Google Scholar
Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009; 11:R142; http://dx.doi.org/10.1186/ar2814; PMID: 19781067
PubMed Web of Science ®Google Scholar
Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 2012; 53:922 - 7; http://dx.doi.org/10.2967/jnumed.111.101006; PMID: 22577235
PubMed Web of Science ®Google Scholar
Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 2013; 107:173 - 9; http://dx.doi.org/10.1002/jso.23168; PMID: 22674435
PubMed Web of Science ®Google Scholar
Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005; 14:2436 - 46; http://dx.doi.org/10.1110/ps.051478705; PMID: 16081651
PubMed Web of Science ®Google Scholar
Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005; 16:1282 - 90; http://dx.doi.org/10.1021/bc050201y; PMID: 16173809
PubMed Web of Science ®Google Scholar
Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26:925 - 32; http://dx.doi.org/10.1038/nbt.1480; PMID: 18641636
PubMed Web of Science ®Google Scholar
Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010; 16:4769 - 78; http://dx.doi.org/10.1158/1078-0432.CCR-10-0987; PMID: 20805300
PubMed Web of Science ®Google Scholar
Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184 - 9; http://dx.doi.org/10.1038/nbt.2108; PMID: 22267010
PubMed Web of Science ®Google Scholar
Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13:729 - 36; http://dx.doi.org/10.1021/bc025517+; PMID: 12121127
PubMed Web of Science ®Google Scholar
Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008; 122:2405 - 13; http://dx.doi.org/10.1002/ijc.23408; PMID: 18271006
PubMed Web of Science ®Google Scholar
Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 2011; 104:1106 - 15; http://dx.doi.org/10.1038/bjc.2011.78; PMID: 21386847
PubMed Web of Science ®Google Scholar
Bernardes GJ, Casi G, Trüssel S, Hartmann I, Schwager K, Scheuermann J, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 2012; 51:941 - 4; http://dx.doi.org/10.1002/anie.201106527; PMID: 22173886
PubMed Web of Science ®Google Scholar
Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10:7063 - 70; http://dx.doi.org/10.1158/1078-0432.CCR-04-0789; PMID: 15501986
PubMed Web of Science ®Google Scholar

References

Mabry R, Snavely M. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. IDrugs 2010; 13:543 - 9; PMID: 20721825
PubMed Web of Science ®Google Scholar
Hess J, Ruf P, Lindhofer H. Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 2012; 8:73 - 85; http://dx.doi.org/10.2217/fon.11.138; PMID: 22149036
PubMed Web of Science ®Google Scholar
Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185 - 7; http://dx.doi.org/10.1182/blood-2012-07-441030; PMID: 23024237
PubMed Web of Science ®Google Scholar
McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 2012; http://dx.doi.org/10.1007/s00262-012-1384-4; PMID: 23263452
PubMed Web of Science ®Google Scholar
Hohlbaum AM, Skerra A. Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies. Expert Rev Clin Immunol 2007; 3:491 - 501; http://dx.doi.org/10.1586/1744666X.3.4.491; PMID: 20477155
PubMedGoogle Scholar

References

Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C, et al, EUROCARE Working Group. The cure of cancer: a European perspective. Eur J Cancer 2009; 45:1067 - 79; http://dx.doi.org/10.1016/j.ejca.2008.11.034; PMID: 19131242
PubMed Web of Science ®Google Scholar
Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14 Suppl 5:v128-49.:v128-v149.
Google Scholar
Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al, Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400 - 4; PMID: 22722201
PubMed Web of Science ®Google Scholar
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al, METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346 - 52; PMID: 22522925
PubMed Web of Science ®Google Scholar
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883 - 92; http://dx.doi.org/10.1056/NEJMoa1113205; PMID: 22397650
PubMed Web of Science ®Google Scholar
Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al, Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell 2012; 149:994 - 1007; http://dx.doi.org/10.1016/j.cell.2012.04.023; PMID: 22608083
PubMed Web of Science ®Google Scholar
Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet 2012; 13:795 - 806; http://dx.doi.org/10.1038/nrg3317; PMID: 23044827
PubMed Web of Science ®Google Scholar
Diaz LA Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486:537 - 40; PMID: 22722843
PubMed Web of Science ®Google Scholar
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532 - 6; PMID: 22722830
PubMed Web of Science ®Google Scholar
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221 - 3; http://dx.doi.org/10.1038/nm.2609; PMID: 22270724
PubMed Web of Science ®Google Scholar
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505 - 9; http://dx.doi.org/10.1038/nature11249; PMID: 22763448
PubMed Web of Science ®Google Scholar
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500 - 4; http://dx.doi.org/10.1038/nature11183; PMID: 22763439
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

8^th Annual European Antibody Congress 2012

November 27–28, 2012, Geneva, Switzerland

References

References

References

References

References

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

8th Annual European Antibody Congress 2012

November 27–28, 2012, Geneva, Switzerland

References

References

References

References

References

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

8^th Annual European Antibody Congress 2012